536974-87-5Relevant academic research and scientific papers
A four-step synthesis of erythro-m-chloro-3-hydroxytyrosine ethyl ester enantiomerically pure
Solladie-Cavallo, Arlette,Nsenda, Thomas
, p. 2191 - 2194 (1998)
Pure erythro-m-chloro-3-hydroxytyrosine having the (2R,3R) configuration, a residue of Vancomycin and Aridicin A, has been prepared in 4 steps using an aldol addition involving a directly generated titanium enolate derived from a chiral iminoglycinate. (+)-Hydroxypinanone was used as a recoverable chiral auxiliary. The (2S,3S)-erythro isomer will be, of course, available from (-)-hydroxypinanone.
Dual aromatase-steroid sulfatase inhibitors
Woo, L. W. Lawrence,Bubert, Christian,Sutcliffe, Oliver-B.,Smith, Andrew,Chander, Surinder K.,Mahon, Mary F.,Purohit, Atul,Reed, Michael J.,Potter, Barry V. L.
, p. 3540 - 3560 (2008/02/09)
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in'vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC 50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.
